Nakayama, Takahiro http://orcid.org/0000-0002-3713-1624
Yoshinami, Tetsuhiro
Yasojima, Hiroyuki
Kittaka, Nobuyoshi
Takahashi, Masato
Ohtani, Shoichiro
Kim, Seung Jin
Kurakami, Hiroyuki
Yamamoto, Naoko
Yamada, Tomomi
Takata, Takehiko
Masuda, Norikazu http://orcid.org/0000-0002-7302-0278
Article History
Received: 17 November 2020
Accepted: 10 June 2021
First Online: 9 July 2021
Declarations
:
: This study was conducted in accordance with the ethical standards found in the 1964 Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and in compliance with the study protocol and all applicable local and national ethical guidelines. This study was approved in ethic screening committee of Osaka Prefectural Hospital Organization Osaka International Cancer Institute. As a non-interventional study with no invasive procedures or human-derived specimens, informed consent was neither required nor obtained from study participants. Participants were able to opt out of the study.
: Not applicable.
: TN has received speakers’ bureau fees from Chugai Pharma, AstraZeneca, Eli Lilly, Novartis, Takeda, Taiho Pharmaceutical, and Daiichi Sankyo. TYo has received consulting or advisory fees from Daiichi Sankyo and speakers’ bureau fees from Chugai Pharma and Novartis. NM has received honoraria from Chugai Pharma, AstraZeneca, Pfizer, Eisai, Eli Lilly, and Takeda; research funding from Chugai Pharma, AstraZeneca, Kyowa Hakko Kirin, MSD, Novartis, Pfizer, Eli Lilly, Eisai, and Daiichi Sankyo; and has a leadership role at the Japan Breast Cancer Research Group. SO has received honoraria from Chugai Pharma, Pfizer, and Eisai. SJK has received honoraria and research funding from Daiichi Sankyo. MT has received honoraria from AstraZeneca, Eisai, Pfizer, Eli Lilly, Chugai Pharma, and Nippon Kayaku; and research funding from Taiho Pharmaceutical, Kyowa Hakko Kirin, Eisai, and Nippon Kayaku. TT is an employee of Daiichi Sankyo. NY has an immediate family member who is an employee of and has owned stock of held ownership interest in Bayer Yakuhin. NK, HK, HY, and TYa have no conflicting interests to declare.